Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), The Cooper's Beta is -0.5516.
The Cooper (MEX:COO) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
The Cooper Beta Related Terms
The Cooper Beta Historical Data
* Premium members only.
The historical data trend for The Cooper's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Beta vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Beta distribution charts can be found below:
* The bar in red indicates where The Cooper's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
The Cooper (MEX:COO) has a Beta of -0.5516 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for The Cooper and its competitors.
Is The Cooper's Beta too high?
The Cooper's current Beta is -0.5516. Overall, The Cooper has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Beta compare to ALGN and SOLV?
The Cooper's Beta of -0.5516 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for The Cooper and its competitors. The Cooper's current Beta is -0.5516. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (MEX:COO) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,702.46, compared to a current price of MXN1,162.20 — trading 31.7% below its estimated fair value. The current Beta is -0.5516. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For The Cooper (MEX:COO), the current Beta is -0.5516 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (MEX:COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of MXN1,162.20 is trading 31.7% below its estimated GF Value™ of MXN1,702.46.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for MEX:COO:
Beta: -0.5516
GF Value™: MXN1,702.46 vs. price of MXN1,162.20 (31.7% below fair value)
No single metric tells the full story. See the MEX:COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for MEX:COO
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:COO has been successfully added to your 
